Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12 Other hematologic neoplasm 9 Thoracic 8 Lymphoid 6 Gynecologic 5 CNS 5 Breast 4 Tumor-Agnostic 3 Sarcoma 2 Plasma cell 2 Head & Neck 2 Genitourinary 2 Dermatologic 2 Myeloid 1 Endocrine 1 Classical hematology 1

Conditions

Adrenocortical Carcinoma 1

Interventions

Everolimus 8 lanreotide 7 Octreotide 7 lutetium Lu 177 dotatate 6 pasireotide 5 Thyrotropin Alfa 5 Mitotane 4 Etoposide 4 Doxorubicin 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 amino-acid, glucose, and electrolyte solution 3 Mifepristone 3 Filgrastim 3 Corlux 3 Cisplatin 3 Chemotherapy, Adjuvant 3 Capecitabine 3 Cabergoline 3 vandetanib 2 telotristat ethyl 2 surufatinib 2 ribociclib 2 fluorodopa F 18 2 cabozantinib 2 Temozolomide 2 Receptor-Like Protein Tyrosine Phosphatases, Class 2 2 Lutetium-177 2 Lutetium 2 Leucovorin 2 Iodine-131 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Observation × Endocrine × Clear all

NCT03723941 2024-08-01

ACACIA

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Phase 3 Completed

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡